Novartis CEO: 4 factors can help the industry price and pay for lifesaving cell and gene therapies

The health-care industry is entering a new era in medicine with the emergence of potentially curative cell and gene therapies. Novartis CEO Vas Narasimhan says there is a fundamental challenge: how to pay for these therapies and make them available to patients in need.